Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

van den Akker TA, Liu Y-, Liu H, Chapman J, Levine JM, Weinberg OK, et al. Myeloid Proliferations Associated with Down Syndrome: Clinicopathologic Characteristics of Forty Cases from Five Large Academic Institutions. Pathobiology. 2024;91(1):89-98.

Morales AE, Gumenick R, Genovese CM, Jang YY, Ouedraogo A, de Garayo MI, et al. Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP. PLoS Pathog. 2024;20(1):e1011881.

Morse KW, Sun J, Hu L, Bok S, Debnath S, Cung M, et al. Development of Murine Anterior Interbody and Posterolateral Spinal Fusion Techniques. J Bone Joint Surg Am. 2024.

Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, et al. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell. 2024.

Solomon JP, Munoz-Zuluaga C, Slocum C, Dillard A, Cong L, Wang J, et al. Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples. Diagn Pathol. 2024;19(1):70.

Torres HM, Marino J, Simon MS, Singh HK, Westblade LF, Calfee DP. High touch surface bioburden associated with the use of disinfectants with and without continuously active disinfection in ambulatory care settings. Infect Control Hosp Epidemiol. 2024:1-3.

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, et al. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Nat Med. 2024;30(8):2170-2180.

Papachristodoulou A, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplaca C, et al. Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. Eur Urol. 2024;85(4):361-372.

Patel SS. NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions. Pathobiology. 2024;91(1):18-29.

Barbhaiya M, Taghavi M, Zuily S, Domingues V, Chock EY, Tektonidou MG, et al. Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. J Rheumatol. 2024;51(2):150-159.